Abstract
Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors. Three subtypes -- PPAR alpha, PPAR beta, and PPAR gamma -- have been identified and are differentially expressed in tissues. Originally, they were described as molecular regulators of lipid metabolism; recently, it has been shown that they are also involved in regulating the cell cycle and apoptosis in both normal and tumoral cells. In fact, some synthetic PPAR ligands are used to treat dyslipidemia, metabolic diseases, and type 2 diabetes. Here, we review the role of PPAR gamma (PPARγ) in tumor initiation and progression, emphasizing the relationship between this isoform and the cellular and molecular mechanisms involved in the antineoplastic effect of iodine on mammary cancer.
Keywords: Antineoplastic, apoptosis, iodine, iodolactone, mammary cancer,, peroxisome proliferator-activated receptor (PPAR), sodium-iodide symporter, prostate specific antigen, thiazolinidinedione, ciglitazone, Peroxisome proliferator response element, non-steroidal anti-inflammatory drugs
Current Cancer Drug Targets
Title: Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Volume: 11 Issue: 7
Author(s): R. E. Nunez-Anita, M. Cajero-Juarez and C. Aceves
Affiliation:
Keywords: Antineoplastic, apoptosis, iodine, iodolactone, mammary cancer,, peroxisome proliferator-activated receptor (PPAR), sodium-iodide symporter, prostate specific antigen, thiazolinidinedione, ciglitazone, Peroxisome proliferator response element, non-steroidal anti-inflammatory drugs
Abstract: Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors. Three subtypes -- PPAR alpha, PPAR beta, and PPAR gamma -- have been identified and are differentially expressed in tissues. Originally, they were described as molecular regulators of lipid metabolism; recently, it has been shown that they are also involved in regulating the cell cycle and apoptosis in both normal and tumoral cells. In fact, some synthetic PPAR ligands are used to treat dyslipidemia, metabolic diseases, and type 2 diabetes. Here, we review the role of PPAR gamma (PPARγ) in tumor initiation and progression, emphasizing the relationship between this isoform and the cellular and molecular mechanisms involved in the antineoplastic effect of iodine on mammary cancer.
Export Options
About this article
Cite this article as:
E. Nunez-Anita R., Cajero-Juarez M. and Aceves C., Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer, Current Cancer Drug Targets 2011; 11 (7) . https://dx.doi.org/10.2174/156800911796798931
DOI https://dx.doi.org/10.2174/156800911796798931 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Irreversible Protein Kinase Inhibitors
Current Medicinal Chemistry Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology Psychiatric Side Effects of Interferon Treatment
Current Drug Safety Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics The Significance of COX-2 and COX-2 Inhibitors in Liver Fibrosis and Liver Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance
Anti-Cancer Agents in Medicinal Chemistry Past, Present, and Future of Targeting Ras for Cancer Therapies
Mini-Reviews in Medicinal Chemistry Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs
Anti-Cancer Agents in Medicinal Chemistry Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer
Current Drug Targets Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry Healthy Properties of Garlic
Current Nutrition & Food Science Drug Delivery Systems for Chemotherapeutics through Selected Polysaccharidic Vehicles
Current Organic Chemistry Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design